A Study of LY3305677 in Participants With Obesity Or Overweight

Lilly

Status and phase: Completed; Phase 1

Conditions: Overweight; Obesity

Treatments: Drug: LY3305677; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05623839

18522

I8P-MC-OXAG (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.

Enrollment: 32 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants who are overtly healthy as determined by medical evaluation
• Participants with stable weight for 3 months and body mass index of 27.0 and 50.0 kilograms per square meter (kg/m²)

Exclusion criteria

• Have history of type 1 diabetes mellitus or type 2 diabetes mellitus, ketoacidosis, or hyperosmolar state or coma

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

32 participants in 2 patient groups, including a placebo group

LY3305677

Experimental group

Description:

LY3305677 administered subcutaneously (SC)

Treatment:

Drug: LY3305677

Placebo

Placebo Comparator group

Description:

Placebo administered SC

Treatment:

Drug: Placebo